Economics of treatments for non-small cell lung cancer

PharmacoEconomics

Volumn 27, Issue 2, 2009, Pages 113-125

  Chouaid, Christos ^a,b,c   Atsou, Kukovi ^a   Hejblum, Gilles ^a,c   Vergnenegre, Alain ^d  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d Cluzeau Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM; VINBLASTINE; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC ASPECT; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; TAXOIDS;

EID: 61749088474     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200927020-00003     Document Type: Review

References (59)

1. Bordeleau L. Pharmacoeconomics of systemic therapies for lung cancer. Treat Respir Med 2006; 5: 129-41
2. Dooms CA, Lievens NY, Vansteenkiste JF. Cost-utility analysis of chemotherapy in symptomatic advanced non small cell lung cancer. Eur Respir J 2006; 27: 895-901
3. Woodward RM, Brown ML, Stewart ST, et al. The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF. Cancer Published Online: 2007; 11: 2511-8
4. Alberts WM. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines. 2nd ed. Chest 2007; 132 [Suppl.]: 1S-19S
5. Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin Oncol 2007; 25: 1898-907
6. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004; 22: 3524-30
7. Chouaid C, Molinier L, Combescure C, et al. Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Br J Cancer 2004; 90: 397-402
8. Du W, Reeves JH, Gadgeel S, et al. Cost-effectiveness and lung cancer clinical trials. Cancer 2003; 98: 1491-6
9. Evans WK, Will BP, Berthelot JM, et al. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer 1995; 72: 1270-7
10. Hillner BE, Smith TJ. Overview of economic analysis of Le Chevalier vinorelbine study. Oncology 1998; 12: 14-7
11. Koopmanschap MA, Van Roijen L, Bonneux L, et al. A detailed description of the future costs of cancer. Eur J Cancer 1994; 30A: 60-5
12. Molinier L, Combescure C, Chouaïd C, et al. Cost of lung cancer: a methodological review. Pharmacoeconomics 2006; 24 (7): 651-9
13. Wolstenholme JL, Whynes DK. The hospital costs of treating lung cancer in the United Kingdom. Br J Cancer 1999; 80: 215-8
14. Braud AC, Lévy-Piedbois C, Piedbois P, et al. Direct treatment costs for patients with lung cancer from first recurrence to death in France. Pharmacoeconomics 2003; 21 (9): 671-9
15. Kutikova L, Bowman L, Chang S, et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 2005; 50: 143-54
16. Fleming I, Monaghan P, Gavin A, et al. Factors influencing hospital costs of lung cancer patients in Northern Ireland. Eur J Health Econ 2008; 9 (1): 79-86
17. National Institute for Clinical Excellence. Lung cancer: the diagnosis and treatment of lung cancer. National cost-impact report. London: NICE, 2005 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/ cg024costings.pdf [Accessed 2007 Dec 28]
18. Ng R, Hasan B, Mittmann N, et al. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer. J Clin Oncol 2007; 25: 2256-61
19. Barbera L, Walker H, Foroudi F, et al. Estimating the benefit and cost of radiotherapy for lung cancer. Int J Technol Assess Health Care 2004; 20: 545-51
20. Robinson LA, Ruckdeschel JC, Wagner H, et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines. 2nd ed. Chest 2007; 132: 243S-65
21. Jett JR, Schild SE, Keith RL, et al. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines. 2nd ed. Chest 2007; 132: 266S-76
22. Evans WK, Will BP, Berthelot JM, et al. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol 1997; 15: 3038-48
23. Vergnenegre A, Combescure C, Fournel P, et al. GFPC (Groupe Français de Pneumo-Cancisérologie). Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01). Ann Oncol 2006; 17: 1269-74
24. Lievens Y, Kesteloot K, Bogaert W. CHART in lung cancer: economic evaluation and incentives for implementation. Radiother Oncol 2005; 75: 171-8
25. Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999; 52: 137-48
26. Kramer GW, Wanders SL, Noordijk EM, et al. Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for nonsmall-cell lung cancer. J Clin Oncol 2005; 23: 2962-70
27. van den Hout WB, Kramer W, Noordijk ED, et al. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. J Nat Cancer Inst 2006; 24: 1786-94
28. Earle CC, Evans WK. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer. Cancer Prev Control 1997; 1: 282-8
29. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004; 10: 828-36
30. Maslove L, Gower N, Spiro S, et al. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer. Thorax 2005; 60: 564-9
31. Billingham LJ, Bathers S, Burton A, et al. Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2002; 37: 219-25
32. Lees M, Aristides M, Maniadakis N, et al. Economic evaluation of gemcitabin alone and combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics 2002; 20 (5): 325-37
33. Jaakkimainen L, Goodwin PJ, Pater J, et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 1990; 8: 1301-9
34. Kennedy W, Reinharz D, Tessier G, et al. Cost utility of chemotherapy and best supportive care in non-small cell lung cancer. Pharmacoeconomics 1995; 8 (4): 316-23
35. Clegg A, Scott DA, Sidhu M, et al. A rapid and systematic review of the clinical effectiveness and costeffectiveness of paclitaxel, docetaxel, gemcitabin and vinorelbine in non-small-cell lung cancer. Health Technol Assess 2001; 5: 1-195
36. Sacristan JA, Kennedy-Martin T, Rosell R, et al. Economic evaluation in a randomized phase III clinical trial comparing gemcitabin/cisplatin and etoposide/cisplatin in nonsmall cell lung cancer. Lung Cancer 2000; 28: 97-107
37. Neymark N, Lianes P, Smit EF, et al. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. Pharmacoeconomics 2005; 23 (11): 1155-66
38. Pimentel FL, Bhalla S, Laranjeira L, et al. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer. Lung Cancer 2006; 52: 365-71
39. Novello S, Kielhorn A, Stynes G, et al. Italian Lung Cancer Project Investigators. Cost-minimisation analysis comparing gemcitabin/cisplatin, paclitaxel/carboplatin and vinorelbine/ cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer 2005; 48: 379-87
40. Rubio-Terrés C, Tisaire JL, Kobina S, et al. Cost-minimisation analysis of three regimens of chemotherapie (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small cell lung cancer. Lung Cancer 2002; 35: 81-9
41. Ramsey SD, Moinpour CM, Lovato LC, et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 2002; 94: 291-7
42. Comella P, Frasci R, Panza N, et al. Randomized trial comparing cisplatin, gemcitabin, and vinorelbine with either cisplatin and gemcitabin or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. Clin Lung Cancer 2000; 1: 202-7
43. Schiller J, Tilden D, Aristides M, et al. Retrospective cost analysis of gemcitabin in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 2004; 43: 101-12
44. Tennvall GR, Fernberg JO. Economic evaluation of gemcitabin single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer. Med Oncol 1998; 15 (2): 129-36
45. Scagliotti GV, De Marinis F, Rinaldi M, et al. Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-91
46. Annemans L, Giaccone G, Vergnenegre A. The cost effectiveness of paclitaxel (taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. Anticancer Drugs 1999; 10: 605-15
47. Earle CC, Evan WK. Cost effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Br J Cancer 1999; 80: 815-20
48. Smith TJ, Hillner BE, Neighbors DM, et al. Economic evaluation of a randomised clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995; 13: 2166-73
49. Maniadakis N, Fragoulakis V, Pallis A, et al. Economic evaluation of docetaxel/gemcitabin versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece. Lung Cancer 2007; 58: 275-81
50. Horn L, Visbal A, Leighl NB. Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics. Drugs Aging 2007; 24: 411-28
51. Le Lay K, Myon E, Hill S, et al. Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ 2007; 8: 145-51
52. Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 1344-52
53. Holmes J, Dunlop D, Hemmett L, et al. A cost-effectiveness analysis of docetaxel in the second-line treatment of nonsmall cell lung cancer. Pharmacoeconomics 2004; 22 (9): 581-9
54. Bushill-Matthews L, Jackson D, Aristides M, et al. Reducing health care burden for the treatment of toxicity associated with pemetrexed or docetaxel in patients with advanced non-small cell lung cancer who previously received chemotherapy: application to the UK setting. Eur J Cancer Suppl 2003; 1: 231
55. Pavlakis N, Mitchell PL, Stynes G. Cost-effectiveness of permetrexed for previously treated advanced non-small cell lung cancer. American Society of Clinical Oncology 2005 May 13-17; Orlando (FL)
56. Chouaid C, Monnet I, Robinet G, et al. Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. Curr Med Res Opin 2007; 23: 1509-15
57. Côté I, Leighl NB, Gyldmark M, et al. Pharmacoeconomic analyses of erlotinib compared with best supportive care (BSC) for the treatment of relapsed non-small cell lung cancer (NSCLC) from the Canadian public health care perspective [abstract]. Value Health 2006; 6: A279
58. Lewis G, Morlotti L, Creeden J, et al. Cost-effectiveness of erlotinib compared with docetaxel for the treatment of relapsed non small cell lung cancer (SNCL) in UK [abstract]. Value Health 2006; 6: A203
59. Carlson JJ, Reyes C, Oestreicher N, et al. Comparative clinical and economic outcomes of treatment for refractory non small cell lung cancers. Lung cancer 2008; 61: 405-15